Issues in adherence to treatment with monoamine oxidase inhibitors and the rate of treatment failure

Journal of Clinical Psychiatry

Volumn 73, Issue SUPPL. 1, 2012, Pages 31-36

  Cohen, Lawrence J ^a,b,c   Sclar, David A ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Washington Institute for Mental Health Research and Training   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

APPLICATION SITE REACTION; DEPRESSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPERTENSIVE CRISIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT PREFERENCE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TRANSDERMAL PATCH; WEIGHT GAIN;

EID: 84864842668     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11096su1c.05     Document Type: Review

References (46)

1. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445. doi:10.176/api.ps.60.1.1439 PubMed
2. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000-1006. PubMed
3. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55(8):694-700. doi:10.101/archpsyc.5.8.694 PubMed
4. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(suppl 8):35-41. PubMed
5. Culpepper L, Kovalick LJ. A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. doi:10.408/PC.v10n0105 PubMed
6. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57(3):99-104. PubMed
7. Balon R, Mufti R, Arfken CL. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv. 1999;50(7):945-947. PubMed
8. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Washington, DC: American Psychiatric Association; 2010. http://psychiatryonline.org/content. aspx?bookid=28§ionid=1667485. Accessed April 17, 2012.
9. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-396. http://www.bap.org.uk/pdfs/antidepressants.pdf. Accessed March 23, 2012. doi:10.17/026981070841 PubMed
10. Lam RW, Kennedy SH, Grigoriadis S, et al, for the Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults, pt 3: pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43. doi:10.1016/j.jad.209.06.041 PubMed
11. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. doi:10.1/j.1524-473.207.0213.x PubMed
12. Akerblad AC, Bengtsson F, von Knorring L, et al. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol. 2006;21(2):117-124. doi:10.1097/01.yic.019452.1682.b8 PubMed
13. Demyttenaere K, Mesters P, Boulanger B, et al. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J Affect Disord. 2001;65(3):243-252. doi:10.1016/S0165-0327(0)025-1 PubMed
14. Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs. 2008;22(11):963-973. doi:10.2165/023210-208210-05 PubMed
15. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869-1875. doi:10.176/api.ajp.159.1.1869 PubMed
16. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64(2):208-214. doi:10.408/JCP.v64n0216 PubMed
17. Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354-1361. doi:10.408/JCP.v67n0905 PubMed
18. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26(6):579-586. doi:10.1097/01.jcp.0239794.37073.70 PubMed
19. Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. Expert Rev Neurother. 2012;12(1):31-37. doi:10.1586/ern.1.178 PubMed
20. Burris JF, Papademetriou V, Wallin JD, et al. Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. Am J Med. 1991;91(1A):S22-S28. doi:10.1016/02-9343(91)9059-7 PubMed
21. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67-74. doi:10.1097/05650-195010-06 PubMed
22. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009;9(1):38. doi:10.186/1471-24X-9-38 PubMed
23. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-1475. doi:10.408/JCP.v64n121 PubMed
24. Birnbaum HG, Ben-Hamadi R, Greenberg PE, et al. Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. Pharmacoeconomics. 2009;27(6):507-517. doi:10.2165/019053- 20927060-06 PubMed
25. Wu EQ, Ben-Hamadi R, Lu M, et al. Treatment persistence and health care costs of adult MDD patients treated with escitalopram vs citalopram in a Medicaid population. Manag Care. 2012;21(1):49-58. PubMed
26. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498- 1504. doi:10.1016/S0140-6736(96)07492-2 PubMed
27. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003. http://www.who.int/chp/knowledge/publications/adherence-report/en. Accessed April 18, 2012.
28. von Knorring L, Akerblad AC, Bengtsson F, et al. Cost of depression: effect of adherence and treatment response. Eur Psychiatry. 2006;21(6):349-354. doi:10.1016/j.eurpsy.206.04.05 PubMed
29. Wade AG, Häring J. A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support. Int Clin Psychopharmacol. 2010;25(5):288-296. doi:10.1097/YIC.0b013e32839fbcf PubMed
30. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry. 2003;64(suppl 18):25-30. PubMed
31. Pampallona S, Bollini P, Tibaldi G, et al. Patient adherence in the treatment of depression. Br J Psychiatry. 2002;180(2):104-109. doi:10.192/bjp.180.2.104 PubMed
32. Bollini P, Pampallona S, Kupelnick B, et al. Improving compliance in depression: a systematic review of narrative reviews. J Clin Pharm Ther. 2006;31(3):253-260. doi:10.1/j.1365-2710.206.073.x PubMed
33. Vergouwen ACM, Bakker A, Katon WJ, et al. Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry. 2003;64(12):1415-1420. doi:10.408/JCP.v64n1203 PubMed
34. Chong WW, Aslani P, Chen TF. Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. Int J Clin Pract. 2011;65(9):954-975. doi:10.1/j.1742-1241.201.02746.x PubMed
35. Lin EH, Von Korff M, Ludman EJ, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry. 2003;25(5):303-310. doi:10.1016/S0163-8343(03)074-4 PubMed
36. Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract. 2009;15(1):34-44. doi:10.1097/01.pra.034917.43780.7 PubMed
37. Farlow MR, Somogyi M. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. Prim Care Companion CNS Disord. 2011;13(6):doi:10.4088/PCC.11r01149. doi:10.408/PC.1r0149
38. Shahiwala A. Formulation approaches in enhancement of patient compliance to oral drug therapy. Expert Opin Drug Deliv. 2011;8(11):1521-1529. doi:10.1517/17425247.201.62831 PubMed
39. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22(5):485-491. doi:10.102/gps.1806 PubMed
40. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26(10):920-935. doi:10.107/s12325-09-075-9 PubMed
41. Pae CU, Lim HK, Han C, et al. Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1153-1163. doi:10.1016/j.pnpbp.207.04.020 PubMed
42. Azzaro AJ, Ziemniak J, Kemper E, et al. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007;47(10):1256-1267. doi:10.17/091270730479 PubMed
43. Robinson DS, Amsterdam JD. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord. 2008;105(1-3):15-23. doi:10.1016/j.jad.207.04.024 PubMed
44. Clayton AH, Campbell BJ, Favit A, et al. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. J Clin Psychiatry. 2007;68(12):1860-1866. doi:10.408/JCP.v68n1205 PubMed
45. Cohen LJ, Sclar DA, Culpepper L, et al. Discussion: a fresh look at monoamine oxidase inhibitors for depression. J Clin Psychiatry 2012;73(suppl 1):42-45.
46. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA. 2002;287(2):203-209. doi:10.101/jama.287.2.203 PubMed